Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1974 Apr;5(4):383–387. doi: 10.1128/aac.5.4.383

Immunological Responsiveness of Tuberculosis Patients Receiving Rifampin

F L Ruben 1, A Winkelstein 1, I G Fotiadis 1
PMCID: PMC428979  PMID: 15825392

Abstract

Rifampin has been shown to impair both humoral and cell-mediated immune responses in animal models. In order to detect a similar effect in man, 11 patients with active tuberculosis were evaluated before, 2 weeks after, and 12 to 16 weeks after initiating rifampin. Several parameters were serially measured including blood lymphocytes, intradermal response to intermediate strength tuberculin (PPD), and in vitro proliferative responses to phytohemagglutinin (PHA), a nonspecific mitogen, and to the specific antigens, PPD and influenza A. No changes in lymphocyte counts were noted. No changes in response were noted 2 weeks after beginning treatment with rifampin. However, compared with initial and 2-week responses, the PHA response was reduced by 47%, the PPD by 68%, and the influenza by 75%, and 6 of 11 patients showed no induration after tuberculin skin testing at the 12- to 16-week point. These results indicate that in doses employed for the treatment of tuberculosis, rifampin has an immunosuppressive effect in man that develops gradually.

Full text

PDF
383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassi L., Di Berardino L., Arioli V., Silvestri L. G., Lignière E. L. Conditions for immunosuppression by rifampicin. J Infect Dis. 1973 Dec;128(6):736–744. doi: 10.1093/infdis/128.6.736. [DOI] [PubMed] [Google Scholar]
  2. Dajani B. M., Canady M. S., Thompson J. S., Kasik J. E. Rifampicin: an immunosuppressant? Lancet. 1972 Nov 18;2(7786):1094–1094. doi: 10.1016/s0140-6736(72)92390-2. [DOI] [PubMed] [Google Scholar]
  3. Dajani B. M., Kasik J. E., Thompson J. S. Effect of rifampin on the immune response in guinea pigs. Antimicrob Agents Chemother. 1973 Apr;3(4):451–455. doi: 10.1128/aac.3.4.451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Graber C. D., Jebaily J., Galphin R. L., Doering E. Light chain proteinuria and humoral immunoincompetence in tuberculous patients treated with rifampin. Am Rev Respir Dis. 1973 May;107(5):713–717. doi: 10.1164/arrd.1973.107.5.713. [DOI] [PubMed] [Google Scholar]
  5. Moshkowitz A., Goldblum N., Heller E. Studies on the antiviral effect of rifampicin in volunteers. Nature. 1971 Feb 5;229(5284):422–424. doi: 10.1038/229422a0. [DOI] [PubMed] [Google Scholar]
  6. Mukerjee P., Schuldt S., Kasik J. E. Effect of rifampin on cutaneous hypersensitivity to purified protein derivative in humans. Antimicrob Agents Chemother. 1973 Dec;4(6):607–611. doi: 10.1128/aac.4.6.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Newman R., Doster B., Murray F. J., Ferebee S. Rifampin in initial treatment of pulmonary tuberculosis. A U.S. Public Health Service tuberculosis therapy trial. Am Rev Respir Dis. 1971 Apr;103(4):461–476. doi: 10.1164/arrd.1971.103.4.461. [DOI] [PubMed] [Google Scholar]
  8. Nilsson B. S. Rifampicin: an immunosuppressant? Lancet. 1971 Aug 14;2(7720):374–374. doi: 10.1016/s0140-6736(71)90087-0. [DOI] [PubMed] [Google Scholar]
  9. Păunescu E. In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature. 1970 Dec 19;228(5277):1188–1190. doi: 10.1038/2281188a0. [DOI] [PubMed] [Google Scholar]
  10. Ruben F. L., Jackson G. G. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis. 1972 Jun;125(6):656–664. doi: 10.1093/infdis/125.6.656. [DOI] [PubMed] [Google Scholar]
  11. Serrou B., Solassol C., Joyeux H., Pujol H., Romieu C. Immunosuppressive effect of rifampicin. Transplantation. 1972 Nov;14(5):654–655. doi: 10.1097/00007890-197211000-00020. [DOI] [PubMed] [Google Scholar]
  12. Vall-Spinosa A., Lester W., Moulding T., Davidson P. T., McClatchy J. K. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med. 1970 Sep 17;283(12):616–621. doi: 10.1056/NEJM197009172831202. [DOI] [PubMed] [Google Scholar]
  13. Verbist L., Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968 Dec;98(6):923–932. doi: 10.1164/arrd.1968.98.6.923. [DOI] [PubMed] [Google Scholar]
  14. Winkelstein A., Ruben R. L., Tolchin S. F., Pollock B. H. Mechanisms of immunosuppression: effect of cyclophosphamide on responses to influenza immunization. J Lab Clin Med. 1974 Mar;83(3):504–510. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES